By continuing to use the site you agree to our Privacy & Cookies policy

Top doctors criticise NICE proposals to significantly expand statin use

A group of leading doctors have criticised plans to advise millions more people to take cholesterol-reducing statins.

The drugs are currently offered to as many as seven million people in the UK who have a 20% risk of developing cardiovascular disease within 10 years.

Draft guidance from the National Institute for Health and Care Excellence (NICE) has called for the NHS to widen this to cover people with just a 10% risk.

“The recent statin recommendations are deeply worrying”

Simon Capewell

But a number of prominent clinicians have written a letter to health secretary Jeremy Hunt to express their concerns.

The signatories, including the president of the Royal College of Physicians and a former chair of the Royal College of General Practitioners, claim that the latest guidance is based almost entirely on studies funded by the pharmaceutical industry.

The group cite findings from non-industry sponsored studies which include an increased risk of developing diabetes in middle aged women taking statins.

Other side effects include fatigue, psychiatric symptoms and erectile dysfunction, the clinicians warn.

They also claim that the “medicalisation of millions of healthy individuals” is unjustified.

One of the signatories is Professor Simon Capewell, professor of clinical epidemiology at the University of Liverpool. He said: “Two decades of research has confirmed the obvious: doctors receiving drug industry funding produce recommendations favouring the industry.

University of Liverpool

Simon Capewell

“NICE urgently need to develop a better mechanism for controlling these conflicts of interests,” he said. “The recent statin recommendations are deeply worrying, effectively condemning all middle aged adults to lifelong medications of questionable value.”

Another signatory London cardiologist Dr Aseem Malhotra said: “Although there is good evidence that the benefits of statins outweigh the potential harms in those with established heart disease, this is clearly not the case for healthy people.

“For example a doctor wouldn’t give chemotherapy to a patient who didn’t have cancer or prescribe insulin to someone without diabetes.

“When you add up doctors’ appointments, unnecessary suffering for those who experience side effects that interfere with the quality of life, the illusion of protection of taking a drug that won’t reduce the risk of death in healthy people - and the increasing burden of chronic disease which is predominantly lifestyle-related - prescribing statins to millions of healthy people would increase costs to the NHS, not reduce it.”

“Our proposals are intended to prevent many lives being destroyed”

Mark Baker

But Professor Mark Baker, director of the centre for clinical practice at NICE, insisted that the draft guidance does not propose that statins should be used instead of lifestyle adjustments by people at risk of cardiovascular disease.

He said: “Cardiovascular disease maims and kills people through coronary heart disease, peripheral arterial disease and stroke. Together, these kill one in three of us. Our proposals are intended to prevent many lives being destroyed.

“We have consulted on these proposals and the results of this consultation are currently being reviewed prior to publication of our final recommendations next month. Our proposals are also being independently peer reviewed to ensure they are reliable and evidence-based.”

Professor Baker stressed that NICE guidance is developed by independent expert committees and none of them support the recommendations to make money for themselves.

Mark Baker

Mark Baker

He added: “This guidance does not medicalise millions of healthy people. On the contrary, it will help prevent many from becoming ill and dying prematurely.

“We recognise that strong views are held by some on both sides of the argument about the best way to use statins, but our job is to reach a balanced judgement. Concerns about hidden data and the bias that the pharmaceutical industry may or may not have are important issues and need to be resolved.

“NICE is part of the effort to do that but just as the signatories to the letter will have done in their professional careers, we need to act in the best interests of patients on the basis of what we know now.”

The full list of signatories:

  • Sir Richard Thompson, president of the Royal College of Physicians
  • Professor Clare Gerada, former chairman of the Royal College of General Practitioners
  • Professor David Haslam, GP and chairman of the National Obesity Forum
  • Dr J S Bamrah, consultant psychiatrist and medical director of Manchester Mental Health and Social Care Trust
  • Dr Malcolm Kendrick, GP and member of the British Medical Association’s General Practitioners sub-committee
  • Dr Aseem Malhotra, London Cardiologist
  • Dr Simon Poole, GP
  • David Newman, assistant professor of emergency medicine and director of clinical research, Mount Sinai School of Medicine, New York
  • Professor Simon Capewell, professor of clinical epidemiology, University of Liverpool

Readers' comments (6)

  • I'm glad someone is speaking out against the general prescribing of statins. I believe that the adverse side effects are underreported simply because the majority of those who currently take statins are elderly. Side effects such as fatigue, erectile dysfunction, diabetes and psychiatric symptoms are easily attributed to the advanced age of the patient being treated. I was put on statins by my GP and suffered extreme fatigue, muscle pain and weakness, and symptoms of depression. Fortunately, (possibly because I am younger) the GP I spoke to took me seriously and took me off statins. Whether the adverse side effects were reported, I don't know.
    Would it not be preferable to check people's cholesterol levels, blood pressure, etc on a regular basis rather than medicating them just in case?

    Unsuitable or offensive?

  • NICE can do whatever they wish but they cannot force people to take medication or any health advice, and especially healthy individuals of any age, against their wishes and better judgement. Such an idea is ludicrous. the fact that some very elderly people remain healthy demonstrates they are very capable of looking after themselves and have not abused their health. Fools the lot of you!

    Unsuitable or offensive?

  • Trish | 11-Jun-2014 12:19 pm

    reptile disfuncion is male rpoblem!

    Unsuitable or offensive?

  • Well done,doctors! The pharmaceutical companies are pulling the strings--keep up tne pressure on these and NICE . These tablets do not safe the lives of healthy people--it is frightening what salesmen can suggest. Looking back I can see how subtle the pressure was--you can end up questioning your own decisions. Ignore the so called evidence --it is about money.

    Unsuitable or offensive?

  • Its very simple the drug companies wish to sell drugs.

    For NICE to recommend this practise I find repugnant.

    As one of the aging population may I point out that all of my friends of 50 plus who were pressed to take statins are now dead or suffering from the side effect of this drug.

    I refused to take this drug 20 years ago and as you can see from my note I am still here.

    Unsuitable or offensive?

  • This difference of 'expert' opinion is doing nothing to assist those of us who work in Primary Care. It is difficult enough to convince the secondary prevention clients of the benefits-where the evidence is far more robust, let alone advocate use in the Primary Prevention 10% risk and over group. The media publish 'anti-statin' propaganda on a daily basis and if the experts can't agree, what chance do we have at the coal-face. Patient choice is going to be the winner here.

    Unsuitable or offensive?

Have your say

You must sign in to make a comment.

Related Jobs

Sign in to see the latest jobs relevant to you!

newsletterpromo